1229516-19-1

Upstream product

• 122715-70-2 (S)-N-(2-(3-(4-(benzyloxy)phenoxy)-2-hydroxypropylamino)ethyl)morpholine-4-carboxamide 
• 110-17-8 (2E)-but-2-enedioic acid 
• 103-16-2 4-Benzyloxyphenol 
• 122797-04-0 (S)-{[4-(Phenylmethoxy)phenoxy]methyl}-oxirane 
• 69630-16-6 N-(2-aminoethyl)-4-morpholine carboxamide 
• 215654-61-8 tert-butyl 2-(3-(morpholine-4-carboxamido)ethyl)carbamate 
• 15159-40-7 4-morpholinocarbonyl chloride 
• 69630-05-3 N-<2--2-hydroxypropyl>amino>ethyl>ethylamine 
• 69630-06-4 phenyl N-<2--2-hydroxypropyl>amino>ethyl>carbamate 
• 76167-36-7 N-<-2-hydroxypropyl>amino>ethyl>-2-methylpropanamide 

Relevant academic research and scientific papers

METHOD OF IMPROVING COGNITION AND SOCIAL BEHAVIOR IN HUMANS HAVING DEFICITS THEREIN DUE TO NEURODEGENERATIVE DISORDERS AND COMPOUNDS AND COMPOSITIONS THEREFOR

A β1-ADR agonist prodrug compound, which is hydrolysable in vivo to release a β1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound relative to the β1-ADR agonist compound.

Phenol esters.

A phenol ester of xamoterol of the formula: wherein X is a methylene radical or a direct bond, R1 is a hydrogen atom or an alkyl or alkenyl radical of 3 to 8 carbon atoms, and R2 and R3, which may be the same or different, are each a 1--4C alkyl radical;